Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT05131815 Completed - Breast Cancer Clinical Trials

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Start date: January 10, 2022
Phase: N/A
Study type: Interventional

The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors. AYAs who were diagnosed with cancer and have completed cancer treatment will be recruited for this study. This study will enroll 20 participants in total and will last approximately 3 months.

NCT ID: NCT05129202 Completed - Clinical trials for Non Small Cell Lung Cancer

Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

OMESIA
Start date: November 3, 2017
Phase:
Study type: Observational

Non-small cell lung cancer patients may have brain metastases at diagnosis. Patients with brain metastasis may contribute as poor prognosis factors. This trial aims to explore the efficacy and the safety of immune checkpoint inhibitors in non small cell lung cancer patients with initial brain metastasis.

NCT ID: NCT05065268 Completed - Brain Tumor Clinical Trials

Visual Rehabilitation in Children With Homonymous Hemianopia: a Pilot Study on Virtual-reality Stimulation

HH-IVR
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

There are currently no visual rehabilitation strategies for children presenting visual field defects consecutive to a brain tumor or its treatment. This study seeks to investigate the use of a home-based stimulation visual rehabilitation program using immerse-virtual reality (IVR) in children aged 4-10 years old with a diagnosis of hemianopia

NCT ID: NCT05054998 Completed - Clinical trials for Metastatic Malignant Solid Neoplasm

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Start date: August 3, 2018
Phase: Phase 4
Study type: Interventional

This phase IV trial studies how well delaying positron emission tomography (PET)/magnetic resonance imaging (MRI) scan after injection of fluorodeoxyglucose (FDG) can improve the imaging of patients with cancer that has spread to brain (brain metastases). FDG is a type of imaging agent that doctors use to help "see" the images on a scan more clearly. Delaying PET/MRI scan after injecting FDG may improve how well doctors can tell the difference between healthy and unhealthy tissue.

NCT ID: NCT04919993 Completed - Primary Brain Tumor Clinical Trials

CBT for Insomnia in Primary Brain Tumor Patients

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to pilot test an empirically supported psychotherapeutic intervention, Cognitive Behavior Therapy for Insomnia (CBT-I) in primary brain tumor patients. Researchers hope to better understand the feasibility and acceptability of this intervention in neuro-oncology, as well as the preliminary potential benefits of this intervention on brain tumor patients' sleep, fatigue, mood, quality of life, and chronic inflammation. This may lead to improvements in treating insomnia in primary brain tumor patients.

NCT ID: NCT04832672 Completed - Clinical trials for The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases

Sequence of Radiation and Targeted Therapy in Brain Metastases

Start date: October 1, 2010
Phase:
Study type: Observational

The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.

NCT ID: NCT04768400 Completed - Brain Tumor Clinical Trials

MEP and Neuromuscular Blocker

Start date: March 9, 2021
Phase: N/A
Study type: Interventional

It is important to predict the influence of the neuromuscular blocking agents on the motor evoked potential. Investigator will investigate the dose-response relationship between the degree of the neuromuscular blockade and the motor evoked potential in patients undergoing brain tumor surgery using the population approach. Investigator will investigate the influence of the other factors such as the impedence, reactance, muscel amount, and age on the motor evoked potential.

NCT ID: NCT04752059 Completed - Clinical trials for Breast Cancer Stage IV

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

TUXEDO-1
Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases

NCT ID: NCT04745715 Completed - Brain Metastases Clinical Trials

Genomic Study in Non-small Cell Lung Cancer Brain Metastasis

Start date: January 1, 2011
Phase:
Study type: Observational

The investigators collected the data from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis. The investigators analysis the correlation of gene mutation and the disease course.

NCT ID: NCT04739761 Completed - Breast Cancer Clinical Trials

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

DESTINY-B12
Start date: June 22, 2021
Phase: Phase 3
Study type: Interventional

This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).